Sarissa Capital Management LP
Follow13F filer, CIK 1577524, GREENWICH, CT
Sarissa Capital Management LP reported $177,878,251 across 10 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000899140-26-000879
- Period
- 2026-06-30
- Reported value
- $178M
- Holdings
- 10
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 0
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| BHVNadded | +19,128 | $285K |
| BIIBnew | +950 | $205K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| INVAreduced | -240,346 | -$5.46M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q2 2026
Share positions as resolved from 13F-HR 0000899140-26-000879, largest first. % of portfolio is the value over $177,878,251, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| INVAINNOVIVA INC | 1,890,604 | $42.9M | 24.14% | -240,346 | Timeline | ||
| IRWDIRONWOOD PHARMACEUTICALS INC | 9,188,635 | $38.7M | 21.75% | 0 | Timeline | ||
| AMRNAMARIN CORP PLC | 1,673,395 | $26.7M | 15% | 0 | Timeline | ||
| NBIXNEUROCRINE BIOSCIENCES INC | 116,533 | $19.6M | 11.04% | 0 | Timeline | ||
| CYTKCYTOKINETICS INC | 228,623 | $19.5M | 10.95% | 0 | Timeline | ||
| LNTHLANTHEUS HLDGS INC | 166,919 | $18.5M | 10.41% | 0 | Timeline | ||
| BHVNBIOHAVEN LTD | 582,312 | $8.66M | 4.87% | +19,128 | Timeline | ||
| REGNREGENERON PHARMACEUTICALS | 4,190 | $2.61M | 1.47% | 0 | Timeline | ||
| VORVOR BIOPHARMA INC | 25,399 | $468K | 0.26% | 0 | Timeline | ||
| BIIBBIOGEN INC | 950 | $205K | 0.12% | new | Timeline |
How Q2 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000899140-26-000879 | base | 2026-08-14 | acceptance time not in the bulk data set |